treosulfan 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | PK/Tox | Related Drugs | BioActivity |

Stem definitionDrug idCAS RN
antineoplastic, alkylating agents, methanesulfonates 2718 299-75-2

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • treosulfan
  • threosulphan
  • treosulphan
  • tresulfan
  • trecondi
immunosuppressant; RN given refers to (S-(R*,R*))-isomer
  • Molecular weight: 278.29
  • Formula: C6H14O8S2
  • CLOGP: -2.20
  • LIPINSKI: 0
  • HAC: 8
  • HDO: 2
  • TPSA: 127.20
  • ALOGS: -1.21
  • ROTB: 7
  • Status: ONP
    • Legend:
    OFP - off patent
    OFM - off market
    ONP - on patent

Drug dosage:

None

ADMET properties:

PropertyValueReference
BA (Bioavailability) 97 % Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H
Vd (Volume of distribution) 0.59 L/kg Lombardo F, Berellini G, Obach RS
CL (Clearance) 4.90 mL/min/kg Lombardo F, Berellini G, Obach RS
t_half (Half-life) 1.83 hours Lombardo F, Berellini G, Obach RS

Predicted pharmacokinetic/toxicological properties (PK-AZ):

PropertyDescriptionValueUnitConfidenceSimilarity
kinase-safety-class ACVR2B,AXL,BRAF,CAMK2D,CDK5,CDK9,DYRK1B,EIF2AK3,ERBB2,GRK2,ITK,MAP2K6,MAPK7,NTRK2,PDK1,PDK2,PDK4,PIK3CG,PRKDC,TEK 20
kinase-selectivity-class ACVRL1,AXL,BMX,BRAF,CAMK2D,CDK1,CDK16,CDK2,CDK3,CDK4,CDK6,CDK7,CDK9,CHUK,DYRK1A,EPHB4,GRK2,GSK3B,IRAK1,IRAK3,IRAK4,MAP2K6,MAP3K21,MAPK7,PDK1,PIK3CB,PIK3CD,PIK3CG,PRKDC,SIK2,SYK,TEK,ZAP70 33
pfas-class PFAS structural alert (1 = True, 0 = False) 0

Approvals:

DateAgencyCompanyOrphan
June 20, 2019 EMA medac Gesellschaft fur klinische Spezialpraparate mbH

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Cytomegalovirus infection reactivation 526.19 86.56 105 2945 7695 90617702
Acute graft versus host disease in skin 314.26 86.56 63 2987 4693 90620704
Adenovirus infection 298.06 86.56 60 2990 4562 90620835
Graft versus host disease in skin 242.32 86.56 49 3001 3804 90621593
Acute graft versus host disease 242.11 86.56 52 2998 5416 90619981
Mucosal inflammation 239.41 86.56 85 2965 57540 90567857
Cytomegalovirus infection 185.36 86.56 58 2992 26544 90598853
Off label use 164.80 86.56 192 2858 1102060 89523337
Human herpesvirus 6 infection 153.91 86.56 33 3017 3399 90621998
Graft versus host disease in gastrointestinal tract 135.05 86.56 31 3019 4357 90621040
Varicella zoster virus infection 133.41 86.56 30 3020 3847 90621550
Adenovirus reactivation 127.57 86.56 19 3031 234 90625163
Chronic graft versus host disease in skin 122.31 86.56 23 3027 1217 90624180
Norovirus infection 119.14 86.56 24 3026 1820 90623577
Skin toxicity 111.87 86.56 29 3021 6750 90618647
Graft versus host disease 106.60 86.56 29 3021 8115 90617282
Acute graft versus host disease in intestine 93.21 86.56 20 3030 2063 90623334

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Cytomegalovirus infection reactivation 385.98 56.44 108 4239 11070 42605918
Cytomegalovirus infection 341.85 56.44 127 4220 32179 42584809
Acute graft versus host disease in skin 289.63 56.44 79 4268 7345 42609643
Graft versus host disease in skin 262.95 56.44 68 4279 5144 42611844
Mucosal inflammation 260.71 56.44 118 4229 49256 42567732
Graft versus host disease in gastrointestinal tract 249.28 56.44 65 4282 5078 42611910
Adenovirus infection 231.21 56.44 65 4282 6744 42610244
Acute graft versus host disease in intestine 144.50 56.44 40 4307 3911 42613077
Off label use 141.84 56.44 240 4107 638095 41978893
Acute graft versus host disease 131.34 56.44 44 4303 8171 42608817
Epstein-Barr virus infection 112.80 56.44 41 4306 9677 42607311
BK virus infection 109.23 56.44 39 4308 8745 42608243
Viral haemorrhagic cystitis 102.28 56.44 26 4321 1828 42615160
Human herpesvirus 6 infection 98.96 56.44 27 4320 2498 42614490
Adenovirus reactivation 98.05 56.44 19 4328 376 42616612
Herpes simplex pneumonia 91.56 56.44 17 4330 265 42616723
Idiopathic pneumonia syndrome 88.01 56.44 18 4329 473 42616515
Cytomegalovirus viraemia 81.69 56.44 33 4314 10344 42606644
Enterocolitis viral 76.81 56.44 16 4331 461 42616527
Product use in unapproved indication 73.46 56.44 92 4255 184364 42432624
Pneumatosis intestinalis 70.21 56.44 24 4323 4728 42612260
Central nervous system viral infection 66.65 56.44 12 4335 156 42616832
Lip ulceration 64.86 56.44 16 4331 994 42615994
Pneumonia respiratory syncytial viral 64.02 56.44 17 4330 1417 42615571
Cytomegalovirus chorioretinitis 59.30 56.44 21 4326 4590 42612398
Venoocclusive liver disease 58.55 56.44 26 4321 10276 42606712

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Cytomegalovirus infection reactivation 795.15 61.56 193 6903 18140 110564063
Adenovirus infection 640.11 61.56 147 6949 10847 110571356
Cytomegalovirus infection 587.33 61.56 193 6903 54251 110527952
Acute graft versus host disease in skin 532.09 61.56 126 6970 10614 110571589
Graft versus host disease in skin 499.83 61.56 114 6982 8140 110574063
Mucosal inflammation 452.60 61.56 185 6911 95956 110486247
Graft versus host disease in gastrointestinal tract 345.69 61.56 86 7010 8882 110573321
Acute graft versus host disease 324.14 61.56 88 7008 12793 110569410
Off label use 321.04 61.56 432 6664 1499753 109082450
Human herpesvirus 6 infection 283.39 61.56 69 7027 6512 110575691
Acute graft versus host disease in intestine 257.54 61.56 62 7034 5577 110576626
Adenovirus reactivation 243.15 61.56 42 7054 698 110581505
Epstein-Barr virus infection 207.92 61.56 68 7028 18670 110563533
Graft versus host disease 171.93 61.56 59 7037 18747 110563456
Cytomegalovirus viraemia 167.35 61.56 57 7039 17707 110564496
BK virus infection 163.50 61.56 52 7044 13054 110569149
Product use in unapproved indication 157.14 61.56 167 6929 447210 110134993
Chronic graft versus host disease in skin 130.98 61.56 31 7065 2588 110579615
Viral haemorrhagic cystitis 127.92 61.56 32 7064 3367 110578836
Epstein-Barr virus infection reactivation 122.09 61.56 32 7064 4052 110578151
Skin toxicity 119.61 61.56 40 7056 11743 110570460
Norovirus infection 113.17 61.56 27 7069 2332 110579871
Multiple organ dysfunction syndrome 111.51 61.56 86 7010 151624 110430579
Infection reactivation 107.83 61.56 29 7067 4052 110578151
Herpes simplex pneumonia 106.92 61.56 19 7077 374 110581829
Autoimmune haemolytic anaemia 103.80 61.56 35 7061 10532 110571671
Cytomegalovirus chorioretinitis 96.02 61.56 30 7066 7098 110575105
Venoocclusive liver disease 91.35 61.56 35 7061 15172 110567031
Thrombotic microangiopathy 90.67 61.56 42 7054 29107 110553096
Varicella zoster virus infection 86.61 61.56 27 7069 6341 110575862
Posterior reversible encephalopathy syndrome 84.68 61.56 42 7054 33819 110548384
Idiopathic pneumonia syndrome 79.97 61.56 17 7079 870 110581333
Epstein-Barr viraemia 78.63 61.56 22 7074 3557 110578646
Parvovirus B19 infection 73.89 61.56 20 7076 2861 110579342
Chronic graft versus host disease 72.35 61.56 26 7070 9431 110572772
Enterocolitis viral 68.79 61.56 15 7081 866 110581337
Staphylococcal infection 68.01 61.56 47 7049 69897 110512306
Viraemia 66.90 61.56 20 7076 4082 110578121
Post transplant lymphoproliferative disorder 66.30 61.56 28 7068 15585 110566618
Pneumonia respiratory syncytial viral 65.46 61.56 18 7078 2731 110579472
Central nervous system viral infection 63.97 61.56 12 7084 322 110581881
Immune thrombocytopenia 62.53 61.56 30 7066 22464 110559739

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

SourceCodeDescription
ATC L01AB02 ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS
ANTINEOPLASTIC AGENTS
ALKYLATING AGENTS
Alkyl sulfonates
MeSH PA D000477 Alkylating Agents
MeSH PA D000970 Antineoplastic Agents
MeSH PA D009676 Noxae
MeSH PA D018906 Antineoplastic Agents, Alkylating
CHEBI has role CHEBI:35610 antineoplastic agent

Related Drugs by ATC class:

L01AB Alkyl sulfonates 2 drugs
busulfanmannosulfan

Drug Use | Suggest Off label Use Form| |View source of the data|

DiseaseRelationSNOMED_IDDOID
Allogeneic peripheral blood stem cell transplant indication 425843001




🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

None

Orange Book patent data (new drug applications)

Formulation strengthTrade nameApplicantApplication numberApproval dateTypeDose formRoutePatent numberPatent expiration datePatent use
1GM/VIAL GRAFAPEX MEDEXUS N214759 Jan. 21, 2025 RX POWDER INTRAVENOUS 7199162 Oct. 12, 2026 ADMINISTERING TREOSULFAN AS A PREPARATIVE REGIMEN FOR ALLOGENEIC STEM CELL TRANSPLANTATION
5GM/VIAL GRAFAPEX MEDEXUS N214759 Jan. 21, 2025 RX POWDER INTRAVENOUS 7199162 Oct. 12, 2026 ADMINISTERING TREOSULFAN AS A PREPARATIVE REGIMEN FOR ALLOGENEIC STEM CELL TRANSPLANTATION

Orange Book exclusivity data (new drug applications)

Formulation strengthTrade nameApplicantApplication numberApproval dateTypeDose formRouteExclusivity dateDescription
1GM/VIAL GRAFAPEX MEDEXUS N214759 Jan. 21, 2025 RX POWDER INTRAVENOUS Jan. 21, 2030 NEW CHEMICAL ENTITY
5GM/VIAL GRAFAPEX MEDEXUS N214759 Jan. 21, 2025 RX POWDER INTRAVENOUS Jan. 21, 2030 NEW CHEMICAL ENTITY
1GM/VIAL GRAFAPEX MEDEXUS N214759 Jan. 21, 2025 RX POWDER INTRAVENOUS Jan. 21, 2032 AS A PREPARATIVE REGIMEN FOR ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION IN ADULT AND PEDIATRIC PATIENTS 1 YEAR OF AGE AND OLDER WITH ACUTE MYELOID LEUKEMIA (AML)
1GM/VIAL GRAFAPEX MEDEXUS N214759 Jan. 21, 2025 RX POWDER INTRAVENOUS Jan. 21, 2032 AS A PREPARATIVE REGIMEN FOR ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION IN ADULT AND PEDIATRIC PATIENTS 1 YEAR OF AGE AND OLDER WITH MYELODYSPLASTIC SYNDROME (MDS)
5GM/VIAL GRAFAPEX MEDEXUS N214759 Jan. 21, 2025 RX POWDER INTRAVENOUS Jan. 21, 2032 AS A PREPARATIVE REGIMEN FOR ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION IN ADULT AND PEDIATRIC PATIENTS 1 YEAR OF AGE AND OLDER WITH ACUTE MYELOID LEUKEMIA (AML)
5GM/VIAL GRAFAPEX MEDEXUS N214759 Jan. 21, 2025 RX POWDER INTRAVENOUS Jan. 21, 2032 AS A PREPARATIVE REGIMEN FOR ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION IN ADULT AND PEDIATRIC PATIENTS 1 YEAR OF AGE AND OLDER WITH MYELODYSPLASTIC SYNDROME (MDS)

Bioactivity Summary:

None

External reference:

IDSource
D07253 KEGG_DRUG
4043722 VANDF
C0076959 UMLSCUI
CHEBI:82557 CHEBI
CHEMBL455186 ChEMBL_ID
DB11678 DRUGBANK_ID
C018404 MESH_SUPPLEMENTAL_RECORD_UI
9882105 PUBCHEM_CID
8281 IUPHAR_LIGAND_ID
3103 INN_ID
CO61ER3EPI UNII
38508 RXNORM
17773 MMSL
d04931 MMSL
004465 NDDF
326774002 SNOMEDCT_US
395912000 SNOMEDCT_US

Pharmaceutical products:

ProductCategoryIngredientsNDCFormQuantityRouteMarketingLabel
GRAFAPEX HUMAN PRESCRIPTION DRUG LABEL 1 59137-335 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION 1000 mg INTRAVENOUS NDA 19 sections
GRAFAPEX HUMAN PRESCRIPTION DRUG LABEL 1 59137-365 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION 5000 mg INTRAVENOUS NDA 19 sections